ReachRxResearch
Home
Research
Sign Up
Beyond the ceiling: A critical analysis of microRNA research in cutaneous T-cell lymphoma and a roadmap forward
Back to Research Hub
  1. Home
  2. Research Hub
  3. Beyond the ceiling: A critical analysis…

Beyond the ceiling: A critical analysis of microRNA research in cutaneous T-cell lymphoma and a roadmap forward

Journal of Investigative Dermatology·September 1Open Access
DermatologyLimited evidenceCutaneous T-Cell LymphomaNarrative ReviewAnti-MicroRNAMicroRNA TherapyMixedCobomarsenCobomarsen

Summary

View source

What was studied

This review critically analyzes 15+ years of microRNA (miRNA) research in cutaneous T-cell lymphoma (CTCL), covering oncogenic/tumor-suppressive networks, JAK/STAT-miRNA signaling, diagnostic classifiers, and therapeutic miRNA targeting (including Cobomarsen, an anti-miR-155 agent).

Key findings

Despite extensive study, no miRNA diagnostic has reached clinical practice; the authors attribute translational stagnation to two core limitations: reliance on bulk-tissue profiling and intrinsic miRNA biology (modest, pleiotropic pathway regulation).

Study limitations

This is a narrative/critical review without systematic search methods or meta-analysis, so conclusions reflect expert synthesis rather than pooled quantitative evidence. No primary patient data or effect sizes are reported.

Clinical implications

miRNA-based diagnostics and therapeutics for CTCL remain investigational; clinicians should not expect validated miRNA assays in the near term. Future advances hinge on single-cell profiling, multiomics integration, and multicenter validation studies.

Caveats

  • Cobomarsen's current regulatory/trial status (as of publication) is not specified in the abstract.
  • No sample size is reported; this is a review article with no primary patient cohort.
  • Sex distribution of underlying studied populations is not reported in the abstract.
Show all 4
  • Study design is described as a 'critical analysis' and roadmap — it is a narrative review, not a systematic review or meta-analysis; level of evidence assigned accordingly.

Related Questions

Explore related topics

What is the current clinical status of Cobomarsen (anti-miR-155) in cutaneous T-cell lymphoma trials?How does JAK/STAT signaling interact with microRNA networks in CTCL pathogenesis?What single-cell or multiomics approaches are being used to advance CTCL biomarker discovery?

Publication Details

Year
2026
Journal
Journal of Investigative Dermatology
Source
View article
Keep scrolling
More content below.
Up Next